Study: Ivermectin and Mebendazole Can Cure Cancer

A pre-print study by N. Hulscher et al titled “Real-World Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort” posted on 7 April 2026 presents more evidence supporting cheap-off-shelf medication that can practically cure cancer.

The main text is about 14 pages, the remaining are references.

The sample initially included 197 adults who had a cancer diagnosis at a median of 1.2 years since initial diagnosis. They underwent the baseline evaluation during August to September 2025, with 122 completing the 6-month follow-up evaluation (61.9% response rate).

The mean age is 67 years (± 10.5 years), male-female proportion is about half, and most are white. Of the 195 who reported their COVID-19 vaccination status, 122 are unvaccinated, 18 received one dose, 33 received two doses and 22 received three or more doses.

The types of cancer are diverse with the top three being prostate (55, 27.9%), breast (36, 18.3%) and lung (17, 8.6%). Most cancers were not spreading (124, 62.9%). Most participants also reported concurrent treatments with the top three being surgery (83, 42.1%), chemotherapy (62, 31.5%) and RT (57, 28.9%).

As for treatment, participants were prescribed oral capsules containing 25 mg ivermectin and 250 mg mebendazole per capsule. Almost half, 54 participants (44.3%), were prescribed one capsule per day, the remaining were prescribed more.

Self-reported cancer status at follow-up was no current evidence of disease in 40 participants (32.8%; 95% CI 25.1–41.5%), regressed in 19 (15.6%; 95% CI 10.2–23.0%), stayed about the same (stable disease) in 44 (36.1%; 95% CI 28.1–44.9%), and spread or progressed in 19 (15.6%; 95% CI 10.2–23.0%).

This corresponds to a Clinical Benefit Ratio of 84.4% (95% CI: 77.0–89.8%).

As for safety, side events were mild with the top three being gastrointestinal symptoms (12, 38.7%), fatigue or weakness (10, 32.3%), and dizziness (7, 22.6%). Some adjusted their dosage; only 2 participants discontinued the treatment.

Interestingly, as one can see in Table 4 reproduced below, there is no significant dose-response for cancer outcomes with about half the cohort having no evidence of disease or in regression. There is, however, a strong association with side effects for those taking two capsules.

Table 4: Dose-response analysis of cancer outcomes and safety at 6-Month follow-up.

The high clinical benefit observed in our cohort is firmly grounded in extensive preclinical evidence demonstrating highly complementary multi-target anticancer mechanisms of ivermectin and mebendazole. Ivermectin exerts at least 14 distinct anti-tumor effects, including potent inhibition of PAK1 kinase, disruption of Wnt/β-catenin, PI3K/Akt/mTOR, and STAT3 signaling, induction of mitochondrial dysfunction, and selective eradication of cancer stem cells. Mebendazole primarily destabilizes microtubules leading to G2/M cell cycle arrest, apoptosis, inhibition of angiogenesis, and disruption of glucose uptake. When used together, these agents target non-overlapping pathways, resulting in synergistic tumor regression, cancer stem cell depletion, and reversal of multidrug resistance in multiple in vitro and in vivo models.

Although the sample is not huge and the study relies on self-reporting as well as the participants having concurrent treatments, it is a real-world cohort with about half having a positive outcome at 6 months.

---

Be sure to subscribe to our mailing list so you get each new Opinyun that comes out!

---